---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-022940"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T21:59:47.922290+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M

## Summary
- FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.
- Loss from continuing operations $34.0M; adjusted EBITDA from cont. ops -$5.8M (vs -$17.8M).
- Commercial cell & gene therapy revenue $33.4M (+29% YoY); supported 760 clinical trials.
- Life Sciences Services revenue $96.5M (+18%); BioStorage/BioServices up 22% to $18.4M.
- Cash & investments $411.2M; repurchased 1.34M shares at avg $7.45 for $10.0M.

## SEC filing metadata
- accession: 0001104659-26-022940
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/0001104659-26-022940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/tm267876d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-022940
- JSON: https://secwatch.observer/filing/0001104659-26-022940.json
- Plain text: https://secwatch.observer/filing/0001104659-26-022940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.